|
1
|
Evance DB, Abbruzzes JL and Rich TA:
Cancer of the pancreas. Cancer, Principles and Practice of
Oncology. DeVita VT Jr, Hellman S and Rosenberg SA: J.B. Lippincott
Co; Philadelphia: pp. 1054–1087. 1997
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al; Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bozic I, Reiter JG, Allen B, Antal T,
Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, et al:
Evolutionary dynamics of cancer in response to targeted combination
therapy. eLife. 2:e007472013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawakami K, Hattori M, Inoue T, Maruyama
Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, et
al: A novel fusicoccin derivative preferentially targets hypoxic
tumor cells and inhibits tumor growth in xenografts. Anticancer
Agents Med Chem. 12:791–800. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mandlekar S and Kong ANT: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Avgeropoulos NG and Batchelor TT: New
treatment strategies for malignant gliomas. Oncologist. 4:209–224.
1999.PubMed/NCBI
|
|
8
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buege JA and Aust SD: Microsomal lipid
peroxidation. Methods Enzymol. 52:302–310. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian Y, Ding W, Wang Y, Ji T, Sun S, Mo Q,
Chen P, Fang Y, Liu J, Wang B, et al: Ubiquitin B in cervical
cancer: Critical for the maintenance of cancer stem-like cell
characters. PLoS One. 8:e844572013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hattori M, Kawakami K, Akimoto M, Takenaga
K, Suzumiya J and Honma Y: Antitumor effect of Japanese apricot
extract (MK615) on human cancer cells in vitro and in vivo through
a reactive oxygen species-dependent mechanism. Tumori. 99:239–248.
2013.PubMed/NCBI
|
|
12
|
Kohli L, Kaza N, Coric T, Byer SJ,
Brossier NM, Klocke BJ, Bjornsti MA, Carroll SL and Roth KA:
4-Hydroxytamoxifen induces autophagic death through K-Ras
degradation. Cancer Res. 73:4395–4405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morad SAF, Levin JC, Tan S-F, Fox TE,
Feith DJ and Cabot MC: Novel off-target effect of tamoxifen -
inhibition of acid ceramidase activity in cancer cells. Biochim
Biophys Acta. 1831:1657–1664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maccarrone M, Fantini C, Ranalli M, Melino
G and Agrò AF: Activation of nitric oxide synthase is involved in
tamoxifen-induced apoptosis of human erythroleukemia K562 cells.
FEBS Lett. 434:421–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nazarewicz RR, Zenebe WJ, Parihar A,
Larson SK, Alidema E, Choi J and Ghafourifar P: Tamoxifen induces
oxidative stress and mitochondrial apoptosis via stimulating
mitochondrial nitric oxide synthase. Cancer Res. 67:1282–1290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Atkinson J, Harroun T, Wassall SR,
Stillwell W and Katsaras J: The location and behavior of
alpha-tocopherol in membranes. Mol Nutr Food Res. 54:641–651. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghafourifar P, Schenk U, Klein SD and
Richter C: Mitochondrial nitric-oxide synthase stimulation causes
cytochrome c release from isolated mitochondria. Evidence for
intramitochondrial peroxynitrite formation. J Biol Chem.
274:31185–31188. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Radi R, Beckman JS, Bush KM and Freeman
BA: Peroxynitrite-induced membrane lipid peroxidation: The
cytotoxic potential of superoxide and nitric oxide. Arch Biochem
Biophys. 288:481–487. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee CJ, Li C and Simeone DM: Human
pancreatic cancer stem cells: Implications for how we treat
pancreatic cancer. Transl Oncol. 1:14–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Honma Y, Ishii Y, Yamamoto-Yamaguchi Y,
Sassa T and Asahi K: Cotylenin A, a differentiation-inducing agent,
and IFN-alpha cooperatively induce apoptosis and have an antitumor
effect on human non-small cell lung carcinoma cells in nude mice.
Cancer Res. 63:3659–3666. 2003.PubMed/NCBI
|
|
23
|
Oecking C, Eckerskorn C and Weiler EW: The
fusicoccin receptor of plants is a member of the 14-3-3 superfamily
of eukaryotic regulatory proteins. FEBS Lett. 352:163–166. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seimiya H, Sawada H, Muramatsu Y, Shimizu
M, Ohko K, Yamane K and Tsuruo T: Involvement of 14-3S3 proteins in
nuclear localization of telomerase. EMBO J. 19:2652–2661. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rittinger K, Budman J, Xu J, Volinia S,
Cantley LC, Smerdon SJ, Gamblin SJ and Yaffe MB: Structural
analysis of 14-3-3 phosphopeptide complexes identifies a dual role
for the nuclear export signal of 14-3-3 in ligand binding. Mol
Cell. 4:153–166. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujita N, Saito S and Tsuruo T:
Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal
protein S6 kinase promotes its binding to 14-3-3 and cytoplasmic
localization. J Biol Chem. 278:49254–49260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Molzan M, Kasper S, Röglin L, Skwarczynska
M, Sassa T, Inoue T, Breitenbuecher F, Ohkanda J, Kato N, Schuler
M, et al: Stabilization of physical RAF/14-3-3 interaction by
cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem
Biol. 8:1869–1875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu Y, Zhu H, Shan H, Lu J, Chang X, Li X,
Lu J, Fan X, Zhu S, Wang Y, et al: Knockdown of Oct4 and Nanog
expression inhibits the stemness of pancreatic cancer cells. Cancer
Lett. 340:113–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herreros-Villanueva M, Bujanda L,
Billadeau DD and Zhang J-S: Embryonic stem cell factors and
pancreatic cancer. World J Gastroenterol. 20:2247–2254. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greenway B, Iqbal MJ, Johnson PJ and
Williams R: Oestrogen receptor proteins in malignant and fetal
pancreas. Br Med J (Clin Res Ed). 283:751–753. 1981. View Article : Google Scholar
|
|
31
|
Benz C, Hollander C and Miller B:
Endocrine-responsive pancreatic carcinoma: Steroid binding and
cytotoxicity studies in human tumor cell lines. Cancer Res.
46:2276–2281. 1986.PubMed/NCBI
|
|
32
|
Singh S, Baker PR, Poulsom R, Wright NA,
Sheppard MC, Langman MJ and Neoptolemos JP: Expression of oestrogen
receptor and oestrogen-inducible genes in pancreatic cancer. Br J
Surg. 84:1085–1089. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mikulski S: Tamoxifen in patients with
advanced pancreatic adenocarcinoma. Oncol Rep. 3:17–19.
1996.PubMed/NCBI
|
|
34
|
Horimi T, Takasaki M, Toki A, Nishimura W
and Morita S: The beneficial effect of tamoxifen therapy in
patients with resected adenocarcinoma of the pancreas.
Hepatogastroenterology. 43:1225–1229. 1996.PubMed/NCBI
|
|
35
|
Lamy R, Conroy T, Brunaud L and Bresler L:
Tamoxifen for metastatic pancreatic adenocarcinoma: A complete
response. Gastroenterol Clin Biol. 25:912–913. 2001.(In
French).
|
|
36
|
Eckel F, Lersch C, Lippl F, Assmann G and
Schulte-Frohlinde E: Phase II trial of cyclophosphamide,
leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in
pancreatic cancer. J Exp Clin Cancer Res. 19:295–300. 2000.
|
|
37
|
Tomao S, Romiti A, Massidda B, Ionta MT,
Farris A, Zullo A, Brescia A, Santuari L and Frati L: A phase II
study of gemcitabine and tamoxifen in advanced pancreatic cancer.
Anticancer Res. 22:2361–2364. 2002.PubMed/NCBI
|
